AstraZeneca's Fasenra offers severe asthma patients 2 years of benefits: analysis

AstraZeneca's Fasenra offers severe asthma patients 2 years of benefits: analysis

Source: 
Fierce Pharma
snippet: 

AstraZeneca’s Fasenra has been stealing share from GlaxoSmithKline’s Nucala in severe asthma, and competition is even fiercer with Sanofi’s Dupixent approval. Now, AZ has released an analysis of several trials showing Fasenra's positive effects for patients last up to two years.